Therapeutic Plasma Exchange: Emerging Evidence for Biological Age Reversal and Alzheimer's Disease

Therapeutic plasma exchange (TPE) is a medical procedure that removes plasma and its soluble components from the blood, replacing it with albumin or donor plasma. While traditionally used for autoimmune disorders, emerging research suggests TPE may have novel applications in biological aging and neurodegenerative disease.

Biological Age Reversal

Recent randomized controlled trials demonstrate that TPE can significantly reduce biological age markers. A 2025 study [1] found that biweekly TPE combined with intravenous immunoglobulin (IVIG) induced biological age rejuvenation across 15 epigenetic clocks compared to placebo (FDR < 0.05). The treatment reversed age-related immune decline and modulated proteins linked to chronic inflammation. Another clinical study [2] showed that TPE promotes a global shift toward a younger systemic proteome, including restoration of pro-regenerative and anti-cancer regulators, while reducing cellular senescence and DNA damage.

The proposed mechanism involves dilution of pro-aging factors in plasma — particularly proteins associated with the senescence-associated secretory phenotype (SASP) — while replenishing beneficial factors [3]. This “plasma dilution” approach appears to reset systemic signaling pathways including JAK-STAT, MAPK, TGF-beta, and NF-κB, which coordinate tissue maintenance and repair.

Alzheimer’s Disease and Cognitive Decline

The landmark AMBAR trial (n=347) demonstrated that TPE with albumin replacement significantly slowed cognitive and functional decline in patients with mild-to-moderate Alzheimer’s disease [5]. Treated patients showed 52% less decline in activities of daily living (p=0.03) and a trend toward 66% less cognitive decline (p=0.06) compared to placebo at 14 months. The effect was most pronounced in moderate-stage patients, who experienced 61% less decline in both cognitive and functional measures.

A 2025 real-world study from Argentina confirmed these findings [4], showing that TPE slowed cognitive decline by 45% compared to historical controls (p<0.001) and reduced memory deterioration by 88% in immediate recall (p<0.001). Neuroimaging analyses revealed that TPE-treated patients had better preservation of hippocampal volume and improved brain metabolism in regions typically affected by Alzheimer’s disease [8].

The therapeutic mechanism likely involves albumin’s ability to bind and clear amyloid-β from the brain, along with its antioxidant and immunomodulatory properties [6][7]. The procedure also removes inflammatory cytokines and other neurotoxic factors from circulation.

Protocol Considerations

It is important to note that not all TPE protocols show equivalent benefit. A 2025 study using plasmapheresis without albumin replacement actually showed acceleration of some epigenetic aging markers [9], suggesting that the replacement fluid and treatment protocol are critical factors in achieving beneficial outcomes. This underscores the importance of physician-supervised, individualized protocols — the approach used at Plasma Life Center.

Safety Profile

TPE has been generally well-tolerated in both aging and Alzheimer’s studies. In the biological aging trial, only two adverse events required discontinuation [1]. In the Alzheimer’s real-world study, 81.5% of 514 procedures were uneventful, with mild-to-moderate adverse events (mainly related to venipuncture) occurring in 18.5% of sessions and no severe events reported [4].

Study	Procedures	Uneventful Rate	Severe Events
Fuentealba 2025 [1]	RCT	High tolerability	2 discontinuations
Taragano 2025 [4]	514	81.5%	None
AMBAR [5]	Phase 2b/3	Well-tolerated	See trial report

Conclusion

TPE represents a promising intervention for both biological age reversal and slowing Alzheimer’s disease progression. The procedure appears to work by removing pro-aging and pro-inflammatory factors while replenishing beneficial proteins, leading to systemic rejuvenation at the molecular and cellular levels. Further research is needed to optimize treatment protocols and identify which patient populations benefit most from this approach.

For more on the science of plasma exchange and aging, see our Aging & Longevity Research page and our review of TPE and longevity evidence. For neurological applications, see Neurological Conditions.